GUIDE-IT NT-proBNP-Guided Therapy Algorithm
Patient data and biomarker target
Compare NT-proBNP with a selected target. This tool does not calculate a validated risk score or prescribe treatment.
Clinical context and use
GUIDE-IT (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) tested whether adjusting evidence-based heart-failure therapy to achieve NT-proBNP below 1,000 pg/mL improved outcomes in high-risk patients with heart failure with reduced ejection fraction (HFrEF).
The randomized trial did not demonstrate a significant improvement in its primary endpoint of time to cardiovascular death or first heart-failure hospitalization with biomarker-guided treatment compared with high-quality usual care. NT-proBNP can support assessment and follow-up, but a target-based strategy should not replace clinical evaluation or guideline-directed treatment.
Practical interpretation
- Assess symptoms, examination findings, and congestion before interpreting a result.
- Review renal function, rhythm (including atrial fibrillation), age, body composition, and other factors affecting NT-proBNP.
- Optimize guideline-directed medical therapy according to current guidelines, contraindications, blood pressure, renal function, potassium, and tolerance—not from the biomarker result alone.
- Compare serial measurements in clinical context and, when practical, using the same assay.
- Do not apply the GUIDE-IT target indiscriminately to HFpEF, acute diagnostic settings, or populations unlike the trial cohort.
Scope and limitations
This tool validates entered values and compares NT-proBNP with a user-selected target. It does not reproduce the full GUIDE-IT protocol, calculate outcome probabilities, determine medication doses, or provide a validated treatment recommendation.
Evidence and references
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.